跳到正文
原文
Medical Xpress·· 2026-10-20AI 评分35

ADK 水平预测三井西林(triciribine)对白血病细胞疗效,提示潜在生物标志物

Higher ADK levels track stronger triciribine effects in leukemia cells, pointing to a potential biomarker

AI 导读

Karolinska Institutet 研究发现,酶 ADK 水平越高,抗白血病药物 triciribine 对细胞的作用越强,ADK 可能作为预测疗效的生物标志物。该研究在实验室培养细胞及 10 份患者样本中验证了这一关联。此前 triciribine 临床试验疗效有限,体内预测价值尚待确立。

正文
Enzyme linked to triciribine response in leukemia cells
Schematic working model summarizing proposed cellular processes associated with TCN activity in ALL cells. Credit: npj Precision Oncology (2026). DOI: 10.1038/s41698-026-01736-z

In a comprehensive study of acute lymphoblastic leukemia, researchers at Karolinska Institutet have shown that the enzyme ADK plays an important role in determining how leukemia cells respond to triciribine. Published in npj Precision Oncology, the study also provides new insights into how the compound works and identifies ADK as a potential biomarker for predicting its effects on leukemia cells.

Acute lymphoblastic leukemia (ALL) is a blood cancer that can affect people of all ages. Triciribine is a compound that has previously been investigated as a cancer treatment, but its mechanism of action in ALL cells has not been fully understood. The researchers therefore set out to investigate how triciribine acts in leukemia cells and why some cells are more susceptible to its effects than others.

To better understand how triciribine works, the researchers used several methods to study a large number of proteins in leukemia cells. This allowed them to map the cellular processes affected by the compound. Their findings suggest that triciribine disrupts several processes that leukemia cells need to grow and divide, including the production of building blocks for DNA and RNA.

One important factor was the enzyme ADK, which is required to convert triciribine into its active form inside the cell. The researchers found that triciribine had a greater effect on laboratory-grown leukemia cells with higher levels of ADK. A similar pattern was observed in 10 patient samples containing leukemia cells exposed to triciribine outside the body.

"We found that ADK levels were associated with the effect of triciribine on leukemia cells. This makes ADK an interesting candidate as a potential biomarker," says Xuekang Qi, a researcher at the Department of Oncology-Pathology and first author of the study.

Previously tested in clinical trials

Triciribine has previously been tested in clinical trials involving patients with blood cancers, but treatment responses have been limited. The new study is based on experiments using laboratory-grown leukemia cells and patient-derived leukemia cells studied outside the body. It therefore remains to be established whether ADK can also predict treatment response in patients.

"If ADK proves able to predict treatment response, it could improve our ability to identify patients who may benefit from triciribine. This is particularly relevant for a compound that has produced limited treatment responses in previous clinical trials," says Rozbeh Jafari, a researcher at the same department and senior author of the study.

Publication details

Xuekang Qi et al., Multi-omics profiling identifies triciribine as a biomarker-guided antimetabolite therapy for acute lymphoblastic leukemia, npj Precision Oncology (2026). DOI: 10.1038/s41698-026-01736-z

Journal information: npj Precision Oncology

Clinical categories

Oncology

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Higher ADK levels track stronger triciribine effects in leukemia cells, pointing to a potential biomarker (2026, October 19) retrieved 19 October 2026 from https://medicalxpress.com/news/2026-10-higher-adk-track-stronger-triciribine.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com